Dashboard
Manage Tickers

ABBVAbbVie Inc.

NYSE abbvie.com


$ 196.54 $ 0.38 (0.19 %)    

Wednesday, 21-Aug-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 482.88 $ 2.24 (0.47 %)
DIA $ 408.91 $ 0.43 (0.11 %)
SPY $ 560.81 $ 1.92 (0.34 %)
TLT $ 98.72 $ 0.06 (0.06 %)
GLD $ 232.16 $ -0.31 (-0.13 %)
$ 196.53
$ 196.47 x 100
-- x --
-- - --
$ 132.11 - $ 197.48
4,250,492
na
348.05B
$ 0.63
$ 65.19
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-03-2024 03-31-2024 10-Q
3 02-20-2024 12-31-2023 10-K
4 11-06-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-05-2023 03-31-2023 10-Q
7 02-17-2023 12-31-2022 10-K
8 11-04-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-06-2022 03-31-2022 10-Q
11 02-18-2022 12-31-2021 10-K
12 11-02-2021 09-30-2021 10-Q
13 08-02-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 02-19-2021 12-31-2020 10-K
16 11-04-2020 09-30-2020 10-Q
17 08-04-2020 06-30-2020 10-Q
18 05-08-2020 03-31-2020 10-Q
19 02-21-2020 12-31-2019 10-K
20 11-06-2019 09-30-2019 10-Q
21 08-05-2019 06-30-2019 10-Q
22 05-03-2019 03-31-2019 10-Q
23 02-27-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-04-2018 03-31-2018 10-Q
27 02-16-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-05-2017 03-31-2017 10-Q
31 02-17-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-Q
34 05-06-2016 03-31-2016 10-Q
35 02-19-2016 12-31-2015 10-K
36 11-06-2015 09-30-2015 10-Q
37 08-07-2015 06-30-2015 10-Q
38 05-08-2015 03-31-2015 10-Q
39 02-20-2015 12-31-2014 10-K
40 11-07-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

unpacking-the-latest-options-trading-trends-in-abbvie
Unpacking the Latest Options Trading Trend...
08/20/2024 20:46:37

100-invested-in-this-stock-10-years-ago-would-be-worth-400-today
$100 Invested In This Stock 10 Years Ago W...
08/20/2024 15:00:17

Core News & Articles
Genmab A/S Announces TEPKINLY Has Received...
08/19/2024 18:01:48

TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both r...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
08/15/2024 17:35:23

Core News & Articles
AbbVie Announces EPKINLY Listing On Ontari...
08/15/2024 13:15:30

decoding-abbvies-options-activity-whats-the-big-picture
Decoding AbbVie's Options Activity: What's...
08/14/2024 17:00:38

cancer-focused-syros-pharmaceuticals-stops-mid-stage-leukemia-combo-therapy-study-cites-disappointing-unexpected-outcome
Cancer-Focused Syros Pharmaceuticals Stops...
08/13/2024 13:41:17

Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demons...

morgan-stanley-maintains-overweight-on-abbvie-raises-price-target-to-218
Morgan Stanley Maintains Overweight on Abb...
08/12/2024 17:29:19

Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $211 to...

Core News & Articles
Botox Innovator Revance Therapeutics Goes ...
08/12/2024 15:50:55

Crown Laboratories will acquire Revance Therapeutics for $924 million, paying $6.66 per share — a premium of 89%.

warren-buffetts-approach-to-investing-in-election-years
Warren Buffett's Approach To Investing In ...
08/07/2024 15:33:49

Warren Buffett, known as the 'Oracle of Omaha', is a highly successful American investor who manages his portfolio cons...

abbvie-leidos-kkr-and-more-on-cnbcs-final-trades
AbbVie, Leidos, KKR And More On CNBC's 'Fi...
08/06/2024 12:43:42

cantor-fitzgerald-reiterates-overweight-on-abbvie-maintains-200-price-target
Cantor Fitzgerald Reiterates Overweight on...
08/05/2024 18:05:52

Cantor Fitzgerald analyst Louise Chen reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $200 price target.

Core News & Articles
CNBC Halftime Report Final Trades: KKR & C...
08/05/2024 17:01:16

heres-how-much-you-would-have-made-owning-abbvie-stock-in-the-last-10-years
Here's How Much You Would Have Made Owning...
08/02/2024 21:00:19

8-health-care-stocks-with-whale-alerts-in-todays-session
8 Health Care Stocks With Whale Alerts In ...
08/01/2024 17:35:24

Core News & Articles
CNBC Halftime Report Final Trades: Amazon....
08/01/2024 17:00:36

a-closer-look-at-abbvies-options-market-dynamics
A Closer Look at AbbVie's Options Market D...
07/31/2024 15:16:03

bristol-myers-johnson--johnson-abbvie-astrazeneca-expect-minimal-impact-from-upcoming-medicare-price-negotiations
Bristol Myers, Johnson & Johnson, AbbVie, ...
07/30/2024 18:12:15

Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact fro...

abbvie-wins-analyst-confidence-with-q2-beat-diverse-portfolio-fuels-long-term-growth-expectations
AbbVie Wins Analyst Confidence with Q2 Bea...
07/26/2024 18:54:10

AbbVie reports Q2 earnings with adjusted EPS of $2.65, surpassing expectations. Net revenues hit $14.46 billion, reflecting a 4...

cantor-fitzgerald-reiterates-overweight-on-abbvie-maintains-200-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/26/2024 17:24:11

Cantor Fitzgerald analyst Louise Chen reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $200 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION